TY - JOUR
T1 - Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides
AU - Prenner, Stuart B.
AU - Mulvey, Claire K.
AU - Ferguson, Jane F.
AU - Rickels, Michael R.
AU - Bhatt, Anish B.
AU - Reilly, Muredach P.
N1 - Funding Information:
This work was supported by a Clinical and Translational Science Award ( UL1RR024134 ) from the National Center for Research Resources and a Diabetes and Endocrine Research Center award ( P20-DK 019525 ), both from the NIH to the University of Pennsylvania, as well as research grants from GlaxoSmithKline and Merck Research Laboratories to M.P.R. M.P.R. is also supported by K24-HL107643 . S.B.P, C.K.M, J.F.F, K.R.R, A.B.B, and M.P.R report no other potential conflicts of interest relevant to this article.
Publisher Copyright:
© 2014 Elsevier Ireland Ltd.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Objective: While recent genomic studies have focused attention on triglyceride (TG) rich lipoproteins in cardiovascular disease (CVD), little is known of very low-density lipoprotein cholesterol (VLDL-C) relationship with atherosclerosis and CVD. We examined, in a high-risk type-2 diabetic population, the association of plasma VLDL-C with coronary artery calcification (CAC). Methods: The Penn Diabetes Heart Study (PDHS) is a cross-sectional study of CVD risk factors in type-2 diabetics (n = 2118, mean age 59.1 years, 36.5% female, 34.1% Black). Plasma lipids including VLDL-C were calculated (n = 1879) after ultracentrifugation. Results: In Tobit regression, VLDL-C levels were positively associated with increasing CAC after adjusting for age, race, gender, Framingham risk score, body mass index, C-reactive protein, exercise, medication and alcohol use, hemoglobin A1c, and diabetes duration [Tobit ratio (TR) and 95% confidence interval (CI) 0.38 (0.12-0.65), P = 0.005] and even after inclusion of apolipoprotein B data [TR 0.31 (0.03-0.58), P = 0.030]. Approximately 3-fold stronger effect was observed in women [TR 0.75 (0.16-1.34), P = 0.013] than men [TR 0.20 (-0.10-0.50), P = 0.189; gender interaction P = 0.034]. Plasma VLDL-C was related more strongly to CAC scores than TG levels (e.g., Akaike information criteria of 7263.65 vs. 7263.94) and had stronger CAC association in individuals with TGs >150 mg/dl (TR 0.80, P = 0.010) vs. those with TGs <150 mg/dl (TR 0.27, P = 0.185). Conclusions: In PDHS, VLDL-C is associated with CAC independent of established CVD risk factors, particularly in women, and may have value even beyond apolipoprotein B levels and in patients with elevated TGs.
AB - Objective: While recent genomic studies have focused attention on triglyceride (TG) rich lipoproteins in cardiovascular disease (CVD), little is known of very low-density lipoprotein cholesterol (VLDL-C) relationship with atherosclerosis and CVD. We examined, in a high-risk type-2 diabetic population, the association of plasma VLDL-C with coronary artery calcification (CAC). Methods: The Penn Diabetes Heart Study (PDHS) is a cross-sectional study of CVD risk factors in type-2 diabetics (n = 2118, mean age 59.1 years, 36.5% female, 34.1% Black). Plasma lipids including VLDL-C were calculated (n = 1879) after ultracentrifugation. Results: In Tobit regression, VLDL-C levels were positively associated with increasing CAC after adjusting for age, race, gender, Framingham risk score, body mass index, C-reactive protein, exercise, medication and alcohol use, hemoglobin A1c, and diabetes duration [Tobit ratio (TR) and 95% confidence interval (CI) 0.38 (0.12-0.65), P = 0.005] and even after inclusion of apolipoprotein B data [TR 0.31 (0.03-0.58), P = 0.030]. Approximately 3-fold stronger effect was observed in women [TR 0.75 (0.16-1.34), P = 0.013] than men [TR 0.20 (-0.10-0.50), P = 0.189; gender interaction P = 0.034]. Plasma VLDL-C was related more strongly to CAC scores than TG levels (e.g., Akaike information criteria of 7263.65 vs. 7263.94) and had stronger CAC association in individuals with TGs >150 mg/dl (TR 0.80, P = 0.010) vs. those with TGs <150 mg/dl (TR 0.27, P = 0.185). Conclusions: In PDHS, VLDL-C is associated with CAC independent of established CVD risk factors, particularly in women, and may have value even beyond apolipoprotein B levels and in patients with elevated TGs.
KW - Subclinical atherosclerosis
KW - Triglycerides
KW - VLDL-C
UR - http://www.scopus.com/inward/record.url?scp=84907084567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907084567&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2014.07.008
DO - 10.1016/j.atherosclerosis.2014.07.008
M3 - Article
C2 - 25105581
AN - SCOPUS:84907084567
SN - 0021-9150
VL - 236
SP - 244
EP - 250
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -